DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma

被引:0
作者
Shan Wei
Jing Xing
Jia Chen
Liping Chen
Jiapei Lv
Xiaofei Chen
Tang Li
Tao Yu
Huaying Wang
Kai Wang
Wanjun Yu
机构
[1] The Affiliated People’s Hospital of Ningbo University (Ningbo Yinzhou People’s Hospital),Department of Respiratory and Critical Care Medicine
[2] Zhejiang University,Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital, School of Medicine
来源
Journal of Experimental & Clinical Cancer Research | / 43卷
关键词
DDB1 and CUL4 associated factor 13; Lung adenocarcinoma; p53 signaling pathway; Ubiquitination; Protein degradation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 134 条
[1]  
Siegel RL(2023)Cancer statistics, 2023 CA Cancer J Clin 73 17-48
[2]  
Miller KD(2016)Non-small cell Lung cancer: current treatment and future advances Transl Lung Cancer Res 5 288-300
[3]  
Wagle NS(2019)Abandoning the notion of Non-small Cell Lung Cancer Trends Mol Med 25 585-94
[4]  
Zappa C(2021)Advances in systemic therapy for non-small cell Lung cancer BMJ 375 n2363-93
[5]  
Mousa SA(2023)Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell Lung cancer: current status and perspectives Biomark Res 11 7-50
[6]  
Relli V(2020)The role of ubiquitination in tumorigenesis and targeted drug discovery Signal Transduct Target Ther 5 11-50
[7]  
Trerotola M(2018)Ubiquitination: friend and foe in cancer Int J Biochem Cell Biol 101 80-70
[8]  
Guerra E(2022)Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation Chem Soc Rev 51 5330-66
[9]  
Miller M(2022)Proteolysis-targeting chimeras (PROTACs) in cancer therapy Mol Cancer 21 99-97
[10]  
Hanna N(2022)Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders Chem Soc Rev 51 6234-70